Drug Trial Radar · NCT07947368
Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the effect of crinecerfont on elevated androstenedione levels in adults with classic CAH on a stable glucocorticoid (GC) dose.
Conditions
- Congenital Adrenal Hyperplasia
Interventions
CrinecerfontDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Serum Androstenedione at Week 24Time frame: Baseline, Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.